LAURUSLABS CMP 795 TARGET 810, SL 789

LAURUSLABS CMP 795 TARGET 810, SL 789

Laurus Labs has captured market attention with a 19% surge in just 11 days, peaking at a record ₹799.4 in July 2025. This rally was ignited by a decisive breakout above the ₹667 on June 9, supported by strong volumes and technical indicators. Today, it has given a breakout above consolidation parallel channel at Rs.796. If it sustains above the price, it keeps a double time of the height of the channel, to reach to Rs.810 with a limited downside of Rs.12, i.e. Rs.789.

Laurus Labs Ltd has seen a notable rise in open interest, reaching 33,498 contracts, alongside a trading volume of 31,641 contracts.

Financially, Laurus Labs delivered a threefold increase in consolidated profit for Q4 FY25, propelled by robust sales and a standout performance in its Contract Development and Manufacturing Organization (CDMO) segment. Quarterly revenue climbed to ₹1,720 crore from ₹1,440 crore a year earlier, while annual profit for FY25 reached ₹358 crore on ₹5,554 crore in revenue.

CEO Satyanarayana Chava and his management team anticipate continued expansion in both human and animal health CDMO divisions, with margin improvements expected as new assets come online and operational execution strengthens.

However, the sector’s volatility—driven by global trade tensions and the threat of US tariffs on pharmaceutical imports—has not spared Laurus Labs. The stock experienced a sharp correction in June 2025 amid these concerns, though management clarified that ongoing penalty proceedings would not impact financials. Despite the recent rally, Laurus Labs is considered overbought in the short term, with analysts urging caution for new entrants and highlighting potential profit-taking zones.